Treatment of tonsillopharyngitis in children

Tonsillopharyngitis is a common disease among pediatric patients. Visits associated with sore throat account for 6 to 8% of all visits to pediatricians and general practitioners. Tonsillopharyngitis can have both infectious and non-infectious etiologies. In pediatric practice, most cases of upper respiratory tract infections are of viral origin, especially in children of early and preschool age. In most cases, uncomplicated course and non-infectious etiology of the disease do not require the administration of antibacterial drugs. The bacterial nature of the disease can be distinguished from the viral one using the data of culture analysis and rapid test for group A β-hemolytic streptococcus (GABHS) or Streptococcus pyogenes. The etiotropic therapy of streptococcal tonsillopharyngitis is antibiotic therapy. In GABHS, antibiotic therapy shortens the duration and reduces the severity of symptoms, reduces the Likelihood of purulent complications, post-streptococcal diseases and prevents the generalization of streptococcal infection. The use of modern antiseptic herbal medicines may be an additional and alternative line of therapy. The authors presented a literature review of the clinical trials results of a modern herbal medicine and provided the results of their own case of the combined treatment of a 10-year-old child with a diagnosis: acute moderate tonsillopharyngitis, bilateral cervical lymphadenitis; acute rhinitis; chronic adenoiditis, exacerbation; degree 2 adenoids. Antibacterial therapy included amoxicillin: oral: 100 mg/kg/day in 2 divided doses for 10 days, combined with an anti-inflammatory and antiseptic herbal medicine due to the complicated course of the disease in the form of concomitant regional lymphadenitis. The course of therapy resulted in clear positive changes: overall well-being improved as early as on the second day of treatment, sore throat and submandibular region ceased to cause pain by 5th day of treatment, the temperature became normal by 5th day of the disease. This clinical observation shows the possibility to introduce an anti-inflammatory herbal medicine to the complex treatment of acute tonsillopharyngitis in children, including cases of complicated course of the disease.

1. Shaikh N., Leonard E., Martin J.M. Prevalence of streptococcal pharyngitis and streptococcal carriage in children: a meta-analysis. Pediatrics. 126(3):e557-e564. doi: 10.1542/peds.2009-2648.

2. Van Driel M.L., De Sutter A.IM., Keber N., Habraken H., Christiaens T. Cochrane Review: Different antibiotic treatments for group A streptococcal pharyngitis. Evidence-Based Child Health. 2012;7(1):16-81. doi: 10.1002/ebch.1805.

3. Savlevich E.L., Doroschenko N.E., Slavinskaya I.S., Farikov S.E. Important factors of the inflammatory process in the o ropharynx and optimal treatment regimes selection. Meditsinskiy sovet = Medical Council. 2017;(16):48-54. (In Russ.) doi: 10.21518/2079-701X-2017-16-48-54.

4. Dawson-Hahn E.E., Mickan S., Onakpoya I., Roberts N., Kronman M., Butler C.C., Thompson MJ. Short-course versus long-course oral antibiotic treatment for infections treated in outpatient settings: a review of systematic reviews. Family Practice. 2017;34(5):511-519. doi: 10.1093/fampra/cmx037.

5. Kolesnikova O.M., Karpishchenko S.A., Legkova Y.V. Anti-inflammatory therapy of throat diseases. Folia Otorhinolaryngologiae et Pathologiae Respiratoriae. 2019;25(3):53-59. (In Russ.) doi: 10.33848/foliorl23103825-2019-25-3-53-59.

6. Kara S.S., Erel O., Demirdag T.B. et al. Alteration of thiol-disulphide homeostasis in acute tonsillopharyngitis. Redox Report. 2017;22(5):205–209. doi: 10.1080/13510002.2016.1173328.

7. Sirenko N.V., Korneenkov A.A., Alekseenko S.I., Artyushkin S.A. Clinical features of peritonsillar abscess in children in a multidisciplinary inpatient department Rossiyskaya otorinolaringologiya=Russian Otorhinolaryngology. 2019;18(5):67–73. (In Russ.) Available at: http://entru.org/files/preview/2019/05/j_rus_LOR_5_2019.pdf.

8. Kaplan E.L. Immunologic impact of tonsillopharyngitis Associated with group A streptococci. Adv Otorhinolaryngol. 2011;72:129–131. doi: 10.1159/000324659.

9. Abdulkerimov Kh.T., Kartashova K.I., Davydov R.S., Abdulkerimov Z.Kh., Kolesnikova A.V., Yusupova D.R. The comparative evaluation of the effectiveness of the treatment of the patients presenting with the sub-compensated form of chronic tonsillitis making use of the antiseptic herbal medicinal product in the combination with the standard conservative therapy: the results of the open randomized study. Vestnik Otorinolaringologii=Bulletin of Otorhinolaryngology. 2018;83(3):45–49. (In Russ.) doi: 10.17116/otorino201883345.

10. Vavilova V.P., Abramov-Sommariva D., Steindl H., Wonnemann M., Ryzhova E.G., Rusova T.V. et al. Clinical effectiveness and tolerability of Tonsilgon®N in the treatment of recurrent upper respiratory tract infections in children: a non-interventional study in Russia. RMZH = RMJ. 2017;(5):350-358. (In Russ.) Available at: https//www.rmj.ru/articles/pediatriya/Klinicheskaya_effektivnosty_i_perenosimosty_preparata_Tonzilgon_N_pri_lechenii_recidiviruyuschih_infekciy_verhnih_dyhatelynyh_putey_u_detey_neintervencionnoe_issledovanie_v_Rossii/

11. Hostanska K., Melzer J., Amon A., Saller R. Suppression of interleukin (IL)-8 and human beta defensin-2 secretion in LPS-and/or IL-1ft-stimulated airway epithelial A549 cells by a herbal formulation against respiratory infections (BNO 1030). J Ethnopharmacol. 2011;134(2):228-233. doi: 10.1016/j.jep.2010.12.006.

12. Drynov G.I., Ivanyushina O.K., D'yakova F.N. Results of therapy for chronic tonsillitis in children using Tonsilgon. Detskiy doctor = Children’s doctor. 2001;(1):67-69. (In Russ.) Available at: https://medi.ru/info/10974/

13. Berger T. Tolerability and efficacy of a herbal combination preparation in children and adolescents with recurrent infections of the upper respiratory tract. MMW Fortschr Med. 2008;150(Suppl 2):85-90. Available at: https://www.ncbi.nlm.nih.gov/pubmed/18712128?dopt=Abstract.